Impact of different doses of ethinyl oestradiol on reduction of final height in constitutionally tall girls

1994 ◽  
Vol 153 (11) ◽  
pp. 797-801 ◽  
Author(s):  
E. E. Joss ◽  
J. Zeuner ◽  
R. P. Zurbrügg ◽  
P. E. Mullis
Keyword(s):  
Final Height ◽  
Tall Girls ◽  
Different Doses ◽  
Ethinyl Oestradiol

Impact of different doses of ethinyl oestradiol on reduction of final height in constitutionally tall girls

1994 ◽  
Vol 153 (11) ◽  
pp. 797-801
Author(s):  
E. E. Joss ◽  
J. Zeuner ◽  
R. P. Zurbr�gg ◽  
P. E. Mullis
Keyword(s):  
Final Height ◽  
Tall Girls ◽  
Different Doses ◽  
Ethinyl Oestradiol

Oestrogen treatment of adolescent tall girls; short term side effects

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S170-S173 ◽  
Author(s):  
OLAV TRYGSTAD
Keyword(s):  
Side Effects ◽  
Idiopathic Scoliosis ◽  
Final Height ◽  
Psychosocial Problems ◽  
Short Term ◽  
Oestrogen Treatment ◽  
Duration Of Therapy ◽  
Tall Girls ◽  
The Mean ◽  
Ethinyl Oestradiol

Abstract In 1980-1985 680 preadolescent tall girls were treated with pharmacological doses of oestrogen to reduce final height. Indications for the therapy were predicted final height >+2.5 SD (180.75 cm), idiopathic scoliosis, and psychosocial problems. Until 1976 141 girls were given diethyl stilboestrol 5 mg daily. By advice of Prader this was then replaced by ethinyl oestradiol and a progestin was given on days 5-10 each month. The mean duration of therapy was close to 2 years. The observed short-term unwanted effects were due to the pharmacological actions of the drugs, (11 girls had galactorrhoea at the end of therapy; no pituitary prolactionoma was observed) or events happening by chance.

Oestrogen treatment of constitutionally tall girls with 0.1 mg/day ethinyl oestradiol

1988 ◽  
Vol 147 (1) ◽  
pp. 59-63 ◽  
Author(s):  
O. Bartsch ◽  
B. Weschke ◽  
B. Weber
Keyword(s):  
Oestrogen Treatment ◽  
Tall Girls ◽  
Ethinyl Oestradiol

scholarly journals REDUCTION OF FINAL HEIGHT IN TALL GIRLS FOLLOWING ESTROGEN ADMINISTRATION IS NOT DOSE DEPENDANT

1986 ◽  
Vol 20 (11) ◽  
pp. 1180-1180 ◽  
Author(s):  
A Grueters ◽  
P Heidemann ◽  
H Schlueter ◽  
P Stubbe ◽  
D I'Allemand ◽  
...  
Keyword(s):  
Final Height ◽  
Tall Girls ◽  
Estrogen Administration

PROTEIN C AND PROTEIN S LEVELS IN TALL GIRLS TREATED WITH ETHINYL -OESTRADIOL

1987 ◽  
Author(s):  
I A Huisveld ◽  
E C G Greven ◽  
B N Bouma
Keyword(s):  
Protein C ◽  
Binding Protein ◽  
Protein S ◽  
Slight Reduction ◽  
Selective Precipitation ◽  
Factor Ii ◽  
Tall Girls ◽  
High Doses ◽  
Ethinyl Oestradiol

Increased levels of several coagulation factors and reduced levels of anti thrombin III (ATIII) have been observed in adults on oestrogen medication and in girls who were treated for excessive tallness with high doses of ethinyloestradiol (E2). In females using oral contraceptives an additional effect on the protein C system has been reported. In our study we evaluated the effect of e-thinyloestradiol treatment (0.1-0.3 mg, administered for at least 6 months) in 14 tall girls (age 14 + 2 yr and height 179 + 4 cm). 13 girls of comparable age (13 + 2 yr) and height 175 + 7 cm) served as controls. Protein C, protein S, C4-binding protein as well as Factor II, plasminogen and ATIII antigen levels were determined by rocket immunoelectrophoresis. ATI11 heparin cofactor ami do-lytic activity was assessed using S2222. Protein S antigen not in complex with C4b-binding protein (PSfree), was assayed in the supernatant plasma after selective precipitation of the protein S-C4b-binding protein complex with PEG 8000. Complete separation of free protein S and PS-C4b-bp complex was verified with crossed immunoelectrophoresis. Results were expressed as % of a normal pool. In the group of girls who were being treated with ethinyl oestradiol (E2-users) significantly higher levels (P<0.001) were observed for protein C (126 ± 29 vs 88 ± 10 in the controls), Factor II (109 ± 18 vs 81 ± 12 in the controls) and plasminogen (131 ± 19 vs 85 ± 9 in the controls). Protein S (58 ± 10 vs 97 ± 8 in the controls) and PSfree (54 ± 11 vs 88 ± 11 in the controls) were sig nificantly reduced (P<0.001) in the E2-users. Only a slight reduction was observed in ATIII antigen levels (95 ± 16 vs 104 ± 9 in the controls) and in the ATIII heparin cofactor activity (105 ± 14 vs 104 ± 9 in the controls). No difference between E2-users and controls was observed in the C4b-binding protein levels (111 ± 25 vs 114 ± 33).Results indicate that treatment of tall girls with high doses of synthetic oestrogens is associated with in vitro signs of hypercoagulability quite comparable to those observed in adult females. However, in contrast to observations made in adults no thromboembolic complications have been reported in juvenile subjects on E2-medication implying additional (aqe-related) variables in the qe-nesis of thrombosis.

scholarly journals Fertility and Ovarian Function in High-Dose Estrogen-Treated Tall Women

2011 ◽  
Vol 96 (4) ◽  
pp. 1098-1105 ◽  
Author(s):  
A. E. J. Hendriks ◽  
J. S. E. Laven ◽  
O. Valkenburg ◽  
S. Lie Fong ◽  
B. C. J. M. Fauser ◽  
...  
Keyword(s):  
Ovarian Function ◽  
Final Height ◽  
Later Life ◽  
Antral Follicle ◽  
High Dose ◽  
Duration Of Treatment ◽  
Ovarian Aging ◽  
Increased Risk ◽  
Tall Girls ◽  
Antral Follicle Counts

Abstract Background/Objective: High-dose estrogen treatment to reduce final height of tall girls has been shown to interfere with fertility. Ovarian function has not been studied. We therefore evaluated fertility and ovarian function in tall women who did or did not receive such treatment in adolescence. Methods: This was a retrospective cohort study of 413 tall women aged 23–48 yr, of whom 239 women had been treated. A separate group of 126 fertile, normoovulatory volunteers aged 22–47 yr served as controls. Results: Fertility was assessed in 285 tall women (157 treated, 128 untreated) who had attempted to conceive. After adjustment for age, treated women were at increased risk of experiencing subfertility [odds ratio (OR) 2.29, 95% confidence interval (CI) 1.38–3.81] and receiving infertility treatments (OR 3.44, 95% CI 1.76–6.73). Moreover, fecundity was notably affected because treated women had significantly reduced odds of achieving at least one live birth (OR 0.26, 95% CI 0.13–0.52). Remarkably, duration of treatment was correlated with time to pregnancy (r = 0.23, P = 0.008). Ovarian function was assessed in 174 tall women (119 treated, 55 untreated). Thirty-nine women (23%) exhibited a hypergonadotropic profile. After adjusting for age category, treated women had significantly higher odds of being diagnosed with imminent ovarian failure (OR 2.83, 95% CI 1.04–7.68). Serum FSH levels in these women were significantly increased, whereas antral follicle counts and serum anti-Müllerian hormone levels were decreased. Conclusion: High-dose estrogen-treated tall women are at risk of subfertility in later life. Their fecundity is significantly reduced. Treated women exhibit signs of accelerated ovarian aging with concomitant follicle pool depletion, which may be the basis of the observed subfertility.

scholarly journals Comparison of height predictions (BAYLEY-PINNEAU vs. TW 2) with final height in tall girls

1981 ◽  
Vol 15 (1) ◽  
pp. 91-91
Author(s):  
R P Willig ◽  
D Christiansen ◽  
N Kuhn ◽  
E Schaefer ◽  
N Stahnke
Keyword(s):  
Final Height ◽  
Tall Girls ◽  
Height Predictions

No effect of vitamin D supplementation on metabolic parameters but on lipids in patients with type 2 diabetes and chronic kidney disease

2020 ◽  
pp. 1-10
Author(s):  
Jiwoon Kim ◽  
Ji Sun Nam ◽  
Heejung Kim ◽  
Hye Sun Lee ◽  
Jung Eun Lee
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Supplementation ◽  
Lipid Profiles ◽  
Metabolic Parameters ◽  
Injection Group ◽  
Different Doses

Abstract. Background/Aims: Trials on the effects of cholecalciferol supplementation in type 2 diabetes with chronic kidney disease patients were underexplored. Therefore, the aim of this study was to investigate the effects of two different doses of vitamin D supplementation on serum 25-hydroxyvitamin D [25(OH)D] concentrations and metabolic parameters in vitamin D-deficient Korean diabetes patients with chronic kidney disease. Methods: 92 patients completed this study: the placebo group (A, n = 33), the oral cholecalciferol 1,000 IU/day group (B, n = 34), or the single 200,000 IU injection group (C, n = 25, equivalent to 2,000 IU/day). 52% of the patients had less than 60 mL/min/1.73m2 of glomerular filtration rates. Laboratory test and pulse wave velocity were performed before and after supplementation. Results: After 12 weeks, serum 25(OH)D concentrations of the patients who received vitamin D supplementation were significantly increased (A, -2.4 ± 1.2 ng/mL vs. B, 10.7 ± 1.2 ng/mL vs. C, 14.6 ± 1.7 ng/mL; p < 0.001). In addition, the lipid profiles in the vitamin D injection group (C) showed a significant decrease in triglyceride and a rise in HDL cholesterol. However, the other parameters showed no differences. Conclusions: Our data indicated that two different doses and routes of vitamin D administration significantly and safely increased serum 25(OH)D concentrations in vitamin D-deficient diabetes patients with comorbid chronic kidney disease. In the group that received the higher vitamin D dose, the lipid profiles showed significant improvement, but there were no beneficial effects on other metabolic parameters.

The Effects of Therapy with Oestriol Succinate and Ethinyl Oestradiol on the Haemostatic Mechanism in Post-Menopausal Women

1976 ◽  
Vol 35 (02) ◽  
pp. 403-414 ◽  
Author(s):  
Terence Davies ◽  
Gillian Fieldhouse ◽  
George P. McNicol
Keyword(s):  
Coagulation Factors ◽  
Factor Vii ◽  
Oestrogen Therapy ◽  
Qualitative And Quantitative ◽  
Lysis Activity ◽  
Menopausal Women ◽  
Increased Sensitivity ◽  
Post Menopausal ◽  
Incremental Increase ◽  
Ethinyl Oestradiol

SummaryThe effects on the haemostatic mechanism of oestrogen therapy, given to prevent bone loss in post-menopausal women, have been investigated. Oestriol succinate was given orally to 10 women at a level of 2 mg/day for 1 month and for a further 3 months with incremental increase of 2 mg each month. 6 of the 10 women were subsequently treated with 25 μg/day orally of ethinyl oestradiol. Oestriol succinate therapy resulted in a small increase in the level of factor VII, a decrease in factor VIII concentration and increased sensitivity of platelets to aggregating agents. Ethinyl oestradiol treatment resulted in much more widespread changes with marked increases in coagulation factors VII, VIII, IX and X, decreased levels of antithrombin and dramatic increases in circulating plasminogen levels and euglobulin lysis activity. The data suggested that the nature of oestrogens employed therapeutically is important in determining the qualitative and quantitative effect of oestrogen therapy on components of the haemostatic mechanism.

Effects of Two Different Doses of Hirudin on APTT, Determined with Eight Different Reagents

1995 ◽  
Vol 73 (02) ◽  
pp. 219-222 ◽  
Author(s):  
Manuel Monreal ◽  
Luis Monreal ◽  
Rafael Ruiz de Gopegui ◽  
Yvonne Espada ◽  
Ana Maria Angles ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Anticoagulant Activity ◽  
Subcutaneous Administration ◽  
In Vitro Study ◽  
Ex Vivo Model ◽  
Suitable Candidate ◽  
Significant Prolongation ◽  
High Doses ◽  
Different Doses

SummaryThe APTT has been considered the most suitable candidate to monitor the anticoagulant activity of hirudin. However, its use is hampered by problems of standardization, which make the results heavily dependent on the responsiveness of the reagent used. Our aim was to investigate if this different responsiveness of different reagents when added in vitro is to be confirmed in an ex vivo study.Two different doses of r-hirudin (CGP 39393), 0.3 mg/kg and 1 mg/kg, were administered subcutaneously to 20 New Zealand male rabbits, and the differences in prolongation of APTT 2 and 12 h later were compared, using 8 widely used commercial reagents. All groups exhibited a significant prolongation of APTT 2 h after sc administration of hirudin, both at low and high doses. But this prolongation persisted 12 h later only when the PTTa reagent (Boehringer Mannheim) was used. In general, hirudin prolonged the APTT most with the silica- based reagents.In a further study, we compared the same APTT reagents in an in vitro study in which normal pooled plasma was mixed with increasing amount of hirudin. We failed to confirm a higher sensitivity for silica- containing reagents. Thus, we conclude that subcutaneous administration of hirudin prolongs the APTT most with the silica-based reagents, but this effect is exclusive for the ex vivo model.

Sign in / Sign up

Export Citation Format

Share Document